HCC Education
Hepatocellular carcinoma management spans locoregional therapies, immunotherapy combinations, and TKI-based systemic treatment — all complicated by underlying liver disease. Knowledge Med sessions help community providers navigate these layered decisions through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing hepatocellular carcinoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting first-line systemic therapy: atezolizumab-bevacizumab vs alternatives
- Assessing liver function (Child-Pugh) alongside tumor staging
- Coordinating locoregional and systemic therapies
- Managing TKI and immunotherapy toxicities in patients with cirrhosis
What Sessions Cover
Knowledge Med HCC sessions use interactive case simulations to address these topics and more.
- First-line immunotherapy combinations in advanced HCC
- TKI sequencing after immunotherapy progression
- Multidisciplinary approach: locoregional therapy integration
- Managing treatment in the context of hepatic impairment
Interactive HCC Sessions
Case Simulations
Work through realistic hepatocellular carcinoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key HCC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a HCC Session
Third-party, non-promotional hepatocellular carcinoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session